Search studies
24 studies found
ABI-IBD
Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.
1
ABI-MS
Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.
2
ABI-RA
Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.
3
EBiSC study
The European Bank for induced pluripotent Stem Cells (EBiSC) is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.
6
EBiSC2 study
The European Bank for induced pluripotent Stem Cells (EBiSC) is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.
7
EUbOPEN wave 1
This submission holds the raw data and processed images for a high-content live-cell multiplex screen. The screen is used for chemogenomic compounnd annotation, i.e. the evaluation of e.g. cytotoxic effects. This submission is about a set of >550 chemogenomic candidate compounds, tested in a pre-screen and a primary screen. Further information about the EUbOPEN project, from which this set and experiment originated can be found in the links section.
8
